title: COMPARISON OF HALVING THE IRRADIATION TIME OR THE VERTEPORFIN DOSE IN PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
abstract: OBJECTIVE
  To compare the efficacy and safety of photodynamic therapy using reduced irradiation time or reduced verteporfin dose for chronic central serous chorioretinopathy.
  
  
  METHODS
  Between April 2011 and December 2013, 45 eyes with chronic central serous chorioretinopathy (43 consecutive patients) were treated with photodynamic therapy, using either half the irradiation time (18 eyes) or half the verteporfin dose (27 eyes). Outcome measures at follow-up, over at least 3 months, were complete resolution of serous retinal detachment, best-corrected visual acuity, and central retinal thickness.
  
  
  RESULTS
  After 3 months, serous retinal detachment had completely resolved in 88.8% of eyes in both treatment groups, which were therefore not significantly different. The logarithm of the minimal angle of resolution best-corrected visual acuity (Snellen equivalent) improved from 0.245 (20/35) to 0.130 (20/27) (P < 0.05, paired t-test) in the reduced time group and from 0.283 (20/38) to 0.138 (20/27) (P < 0.05) in the reduced verteporfin group. Final best-corrected visual acuities in the 2 groups were not significantly different. Central retinal thicknesses dropped from 337.0 μm to 146.6 μm (P < 0.05) in the reduced time group and from 343.5 μm to 166.9 μm (P < 0.05) in the reduced verteporfin group. No ocular or systemic side effects were observed.
  
  
  CONCLUSIONS
  Reduced irradiation time and reduced verteporfin dose were equally effective and safe in photodynamic therapy for chronic central serous chorioretinopathy.
authors.affiliation: Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Shiode
authors.forename: Yuki
authors.initials: Y
authors.lastname: Morizane
authors.forename: Shuhei
authors.initials: S
authors.lastname: Kimura
authors.forename: Mio
authors.initials: M
authors.lastname: Hosokawa
authors.forename: Tetsuhiro
authors.initials: T
authors.lastname: Kawata
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Doi
authors.forename: Mika
authors.initials: M
authors.lastname: Hosogi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Fujiwara
authors.forename: Fumio
authors.initials: F
authors.lastname: Shiraga
mesh_terms: D000328:Adult; D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000378:metabolism; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011166:Porphyrins / Q000008:administration & dosage*; D012163:Retinal Detachment / Q000188:drug therapy; D012189:Retrospective Studies; D058471:Subretinal Fluid / Q000378:metabolism; D013997:Time Factors; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin